Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).

@article{Morganroth2010EvaluationAM,
  title={Evaluation and management of cardiac safety using the electrocardiogram in oncology clinical trials: focus on cardiac repolarization (QTc interval).},
  author={Joel Morganroth and Rashmi R Shah and John W Scott},
  journal={Clinical pharmacology and therapeutics},
  year={2010},
  volume={87 2},
  pages={166-74}
}
Non-antiarrhythmic drugs have been reported to prolong the QTc interval and induce potentially fatal ventricular tachyarrhythmias. An increasing number of drugs that are used for treating malignancies are no exception. Therefore, both oncologists and regulators expect sponsors of oncology drugs to evaluate, during the development of the drugs, their effects on the electrocardiogram (ECG), particularly on the QTc interval. In the case of agents that cannot be administered to healthy volunteers… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.

Expert opinion on drug safety • 2014
View 18 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Experience in QT evaluation of oncology drug products since ICH E 14 guidance

Q. Liu, R. Madabushi, C. Garnett, B. Booth
Proceedings of 2008 american Society of Clinical Oncology annual Meeting , J . Clin . Oncol . • 2008

Similar Papers

Loading similar papers…